These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 23208671)

  • 1. Pretest genetic counseling informs patients with BRCA mutation.
    Printz C
    Cancer; 2012 Dec; 118(24):6017. PubMed ID: 23208671
    [No Abstract]   [Full Text] [Related]  

  • 2. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
    Euhus DM; Smith KC; Robinson L; Stucky A; Olopade OI; Cummings S; Garber JE; Chittenden A; Mills GB; Rieger P; Esserman L; Crawford B; Hughes KS; Roche CA; Ganz PA; Seldon J; Fabian CJ; Klemp J; Tomlinson G
    J Natl Cancer Inst; 2002 Jun; 94(11):844-51. PubMed ID: 12048272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis.
    Quinn GP; Vadaparampil ST; Bower B; Friedman S; Keefe DL
    Minerva Med; 2009 Oct; 100(5):371-83. PubMed ID: 19910890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic counseling and management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations.
    Silva E; Lynch H
    Breast J; 2006; 12(3):280-1; author reply 282-4. PubMed ID: 16684334
    [No Abstract]   [Full Text] [Related]  

  • 5. BRCA1 and BRCA2 cancer risks.
    Antoniou AC; Pharoah PD; Easton DF; Evans DG
    J Clin Oncol; 2006 Jul; 24(20):3312-3; author reply 3313-4. PubMed ID: 16829658
    [No Abstract]   [Full Text] [Related]  

  • 6. High-risk women should have BRCA testing.
    Cancer Discov; 2014 Feb; 4(2):139. PubMed ID: 24501290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
    Wolff TA; Wilson JE
    Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
    [No Abstract]   [Full Text] [Related]  

  • 8. One risk fits all?
    De Bock GH; Mourits MJ; Oosterwijk JC
    J Clin Oncol; 2007 Aug; 25(22):3383-4; author reply 3384. PubMed ID: 17664491
    [No Abstract]   [Full Text] [Related]  

  • 9. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA testing: ethics lessons for the new genetics.
    Sherwin S
    Clin Invest Med; 2004 Feb; 27(1):19-22. PubMed ID: 15061582
    [No Abstract]   [Full Text] [Related]  

  • 11. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.
    Leegte B; van der Hout AH; Deffenbaugh AM; Bakker MK; Mulder IM; ten Berge A; Leenders EP; Wesseling J; de Hullu J; Hoogerbrugge N; Ligtenberg MJ; Ardern-Jones A; Bancroft E; Salmon A; Barwell J; Eeles R; Oosterwijk JC
    J Med Genet; 2005 Mar; 42(3):e20. PubMed ID: 15744030
    [No Abstract]   [Full Text] [Related]  

  • 12. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inherited breast and ovarian cancers].
    Gerdes AM; Ejlertsen B
    Ugeskr Laeger; 2006 Jun; 168(24):2367-9. PubMed ID: 16822422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
    Olopade OI
    Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer.
    Calzone KA; Prindiville SA; Jourkiv O; Jenkins J; DeCarvalho M; Wallerstedt DB; Liewehr DJ; Steinberg SM; Soballe PW; Lipkowitz S; Klein P; Kirsch IR
    J Clin Oncol; 2005 May; 23(15):3455-64. PubMed ID: 15908654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 24366402
    [No Abstract]   [Full Text] [Related]  

  • 17. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 25006622
    [No Abstract]   [Full Text] [Related]  

  • 19. Familial breast and ovarian cancers.
    Arai M; Utsunomiya J; Miki Y
    Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of proband mediated information dissemination in families with a BRCA1/2 gene mutation.
    Sermijn E; Goelen G; Teugels E; Kaufman L; Bonduelle M; Neyns B; Poppe B; De Paepe A; De Grève J
    J Med Genet; 2004 Mar; 41(3):e23. PubMed ID: 14985394
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.